Quantification of hepatitis B surface antigen: A new concept for the management of chronic hepatitis B

Liver International

Volumn 31, Issue SUPPL. 1, 2011, Pages 122-128

  Moucari, Rami ^a   Marcellin, Patrick ^a  

^a BEAUJON HOSPITAL   (France)

Author keywords

CccDNA; HBeAg; HBsAg; HBV; Hepatitis B; Peginterferon

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; VIRUS DNA;

ANTIGEN DETECTION; ARTICLE; AUTOMATION; HEPATITIS B; HUMAN; LIVER CELL CARCINOMA; NONHUMAN; PATIENT MONITORING; PATIENT SELECTION; PREDICTOR VARIABLE; QUANTITATIVE ANALYSIS; TREATMENT OUTCOME; TREATMENT RESPONSE;

DISEASE MANAGEMENT; DNA, VIRAL; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS;

EID: 78650825940     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2010.02390.x     Document Type: Article

References (68)

1. Blumberg BS, Alter HJ, Visnich S. A 'New' antigen in leukemia sera. JAMA 1965; 191: 541-6.
2. Rotman Y, Brown AT, Hoofnagle JH. Evaluation of the patient with hepatitis B. Hepatology 2009; 49: S22-7.
3. Moucari R, Lada O, Marcellin P. Chronic hepatitis B: back to the future with HBsAg. Expert Rev Anti Infect Ther 2009; 7: 633-6.
4. Chu CM, Liaw YF. Hepatitis B surface antigen seroclearance during chronic hepatitis B. Antivir Ther 2010; 15: 133-43.
5. Ganem D, Prince AM. Hepatitis B virus infection - natural history and clinical consequences. N Engl J Med 2004; 350: 118-29.
6. Liang TJ. Hepatitis B: the virus and disease. Hepatology 2009; 49: S13-21.
7. Stibbe W, Gerlich WH. Variable protein composition of hepatitis B surface antigen from different donors. Virology 1982; 123: 436-42.
8. Vanlandschoot P, Leroux-Roels G. Viral apoptotic mimicry: an immune evasion strategy developed by the hepatitis B virus? Trends Immunol 2003; 24: 144-7.
9. Madalinski K, Burczynska B, Heermann KH, et al. Analysis of viral proteins in circulating immune complexes from chronic carriers of hepatitis B virus. Clin Exp Immunol 1991; 84: 493-500.
10. Simon K, Lingappa VR, Ganem D. Secreted hepatitis B surface antigen polypeptides are derived from transmembrane precursor. J Cell Biol 1988; 107: 2163-8.
11. De Medina T, Kaktor O, Shaul Y. The S promoter of HBV is regulated by positive and negative elements. Mol Cell Biol 1988|; 46: 2449-55.
12. Stibbe W, Gerlich WH. Structural relationship between minor and major proteins of hepatitis B surface antigen. J Virol 1983; 46: 626-8.
13. Heermann KH, Goldmann U, Schwartz W, et al. Large surface proteins of HBV containing the pre-s sequence. J Virol 1984; 45: 369-402.
14. Dienes HP, Gerlich WH, Worsdorfer M, et al. Hepatic expression patterns of the large and middle hepatitis B surface proteins in viremic and non viremic chronic hepatitis B. Gastroenterology 1990; 98: 1017-23.
15. Lau JYN, Bain VG, Davies SE, et al. Export of intracellular HBsAg in chronic hepatitis B virus infection is related to viral replication. Hepatology 1991; 14: 416-21.
16. Seeger C, Mason WS. Hepatitis B virus biology. Microbiol Mol Biol Rev 2000; 64: 51-68.
17. Kimbi GC, Kramvis A, Kew MC. Integration of hepatitis B virus DNA into chromosomal DNA during acute hepatitis B. World J Gastroenterol 2005; 11: 6416-21.
18. Bill CA, Summers J. Genomic DNA double-strand breaks are targets for hepadnaviral DNA integration. Proc Natl Acad Sci USA 2004; 101: 11135-40.
19. Nagaya T, Nakamura T, Tokino T, et al. The mode of hepatitis B virus DNA integration in chromosomes of human hepatocellular carcinoma. Genes Dev 1987; 1: 773-82.
20. Thomas HC, Lemon S, Zuckerman AJ. Viral Hepatitis, 3rd ed. Massachusetts, USA: Blackwell Publishing, 2005.
21. Marcellin P, Asselah T, Boyer N. Treatment of chronic hepatitis B. J Viral Hepat 2005; 12: 333-45.
22. Lee WM. Hepatitis B virus infection. N Engl J Med 1997; 337: 1733-45.
23. Marcellin P, Pequignot F, Delarocque-Astagneau E, et al. Mortality related to chronic hepatitis B and chronic hepatitis C in France: evidence for the role of HIV coinfection and alcohol consumption. J Hepatol 2008; 48: 200-7.
24. Chu CM, Liaw YF. Hepatitis B virus-related cirrhosis: natural history and treatment. Semin Liver Dis 2006; 26: 142-52.
25. Liaw YF, Chu CM. Hepatitis B virus infection. Lancet 2009; 373: 582-92.
26. Hsu YS, Chien RN, Yeh CT, et al. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology 2002; 35: 1522-7.
27. Chu CM, Hung SJ, Lin J, Tai DI, Liaw YF. Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal serum aminotransferase levels. Am J Med 2004; 116: 829-34.
28. Liaw YF, Sheen IS, Chen TJ, Chu CM, Pao CC. Incidence, determinants and significance of delayed clearance of serum HBsAg in chronic hepatitis B virus infection: a prospective study. Hepatology 1991; 13: 627-31.
29. Chu CM, Liaw YF. HBsAg seroclearance in asymptomatic carriers of high endemic areas: appreciably high rates during a long-term follow-up. Hepatology 2007; 45: 1187-92.
30. Fattovich G, Olivari N, Pasino M, et al. Long-term outcome of chronic hepatitis B in Caucasian patients: mortality after 25 years. Gut 2008; 57: 84-90.
31. Manno M, Cammá C, Schepis F, et al. Natural history of chronic HBV carriers in northern Italy: morbidity and mortality after 30 years. Gastroenterology 2004; 127: 756-63.
32. van Zonneveld M, Honkoop P, Hansen BE, et al. Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B. Hepatology 2004; 39: 804-10.
33. Moucari R, Korevaar A, Lada O, et al. High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: a long-term follow-up study. J Hepatol 2009; 50: 1084-92.
34. Lok AS, Chung HT, Liu VW, Ma OC. Long-term follow-up of chronic hepatitis B patients treated with interferon alfa. Gastroenterology 1993; 105: 1833-8.
35. Yuen MF, Hui CK, Cheng CC, et al. Long-term follow-up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: the effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications. Hepatology 2001; 34: 139-45.
36. Yuen MF, Wong DK, Fung J, et al. HBsAg Seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma. Gastroenterology 2008; 135: 1192-9.
37. Arase Y, Ikeda K, Suzuki F, et al. Long-term outcome after hepatitis B surface antigen seroclearance in patients with chronic hepatitis B. Am J Med 2006; 119: 71.e9-16.
38. Loriot MA, Marcellin P, Walker F, et al. Persistence of hepatitis B virus DNA in serum and liver from patients with chronic hepatitis B after loss of HBsAg. J Hepatol 1997; 27: 251-8.
39. Simonetti J, Bulkow L, McMahon BJ, et al. Clearance of hepatitis B surface antigen and risk of hepatocellular carcinoma in a cohort chronically infected with hepatitis B virus. Hepatology 2010; 51: 1531-7.
40. Chen YC, Sheen IS, Chu CM, Liaw YF. Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection. Gastroenterology 2002; 123: 1084-9.
41. Lau GKK. Hepatitis B reactivation after chemotherapy: two decades of clinical research. Hepatol Int 2008; 2: 152-62.
42. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis. B. J Hepatol 2009; 50: 227-42.
43. Whitehead TP, Thorpe GHG, Carter TJN, Groucutt C, Kricka LJ. Enhanced luminescence procedure for sensitive determination of peroxidase-labelled conjugates in immunoassay. Nature 1983; 305: 158-9.
44. Janssen HL, Kerhof-Los CJ, Heijtink RA, Schalm SW. Measurement of HBsAg to monitor hepatitis B viral replication in patients on alpha-interferon therapy. Antiviral Res 1994; 23: 251-7.
45. Deguchi M, Yamashita N, Kagita M, et al. Quantitation of hepatitis B surface antigen by an automated chemiluminescent microparticle immunoassay. J Virol Methods 2004; 115: 217-22.
46. Galli C, Orlandini E, Penzo L, et al. What is the role of serology for the study of chronic hepatitis B virus infection in the age of molecular biology? J Med Virol 2008; 80: 974-9.
47. Brunetto MR, Moriconi F, Bonino F, et al. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology 2009; 49: 1141-50.
48. Moucari R, Mackiewicz V, Lada O, et al. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology 2009; 49: 1151-7.
49. Rijckborst V, Hansen BE, Cakaloglu Y, et al. Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels. Hepatology 2010; 52: 454-61.
50. Moucari R, Boyer N, Ripault MP, et al. Sequential therapy with adefovir dipivoxil and pegylated interferon alfa-2a for HBeAg-negative patients. J Viral Hepat 2010. DOI: DOI: 10.1111/j.1365-2893.2010.01332.x.
51. Lau GK, Marcellin P, Brunetto M, et al. On-treatment HBsAg decline during peginterferon alfa-2a (40 kD)±lamivudine in patients with HBeAg-positive CHB as a potential predictor of durable off-treatment response. Hepatology 2008; 48: 714A.
52. Sonneveld MJ, Rijckborst V, Boucher CA, et al. Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline. Hepatology 2010; 52: 1251-7.
53. Moucari R. Peginterferon for chronic hepatitis B: predicting success with on-treatment benchmarks. J Gastroenterol Hepatol 2010; 25: 1474-5.
54. Wursthorn K, Jung M, Manns MP, t al. Kinetics of HBsAg decline in HBeAg+chronic hepatitis B patients with 3 years of telbivudine treatment during the Globe study. J Hepatol 2009; 50: S9.
55. Nguyen T, Thompson AJ, Bowden S, et al. Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia. J Hepatol 2010; 52: 508-13.
56. Jaroszewicz J, Calle Serrano B, Wursthorn K, et al. Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective. J Hepatol 2010; 52: 514-22.
57. Brunetto MR, Oliveri F, Colombatto P, et al. Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers. Gastroenterology 2010; 139: 483-90.
58. Werle-Lapostolle B, Bowden S, Locarnini S, et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 2004; 126: 1750-8.
59. Wursthorn K, Lutgehetmann M, Dandri M, et al. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology 2006; 44: 675-84.
60. Volz T, Lutgehetmann M, Wachtler P, et al. Impaired intrahepatic hepatitis B virus productivity contributes to low viremia in most HBeAg-negative patients. Gastroenterology 2007; 133: 843-52.
61. Lu L, Ye D, Wang Y, et al. Correlation between HBV cccDNA and HBsAg levels and their reduction by peginterferon alfa-2a based therapy in patients with chronic hepatitis B. Hepatology 2008; 48 (Suppl. 1): 746A.
62. Manesis EK, Papatheodoridis GV, Hadziyannis E, et al. HBsAg serum levels correlate with total liver HBV DNA but not with cccDNA. Hepatology 2008; 48 (Suppl. 1): 371A.
63. Chan HL, Wong VW, Wong GL, et al. A longitudinal study on the natural history of serum hepatitis B surface antigen changes in chronic hepatitis B. Hepatology 2010; 52: 1232-41.
64. Laras A, Koskinas J, Dimou E, et al. Intrahepatic levels and replicative activity of covalently closed circular hepatitis B virus DNA in chronically infected patients. Hepatology 2006; 44: 694-702.
65. Thompson AJ, Nguyen T, Iser D, et al. Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers. Hepatology 2010; 51: 1933-44.
66. Biermer M, Puro R, Schneider RJ. Tumor necrosis factor alpha inhibition of hepatitis B virus replication involves disruption of capsid integrity through activation of NF-kappaB. J Virol 2003; 77: 4033-42.
67. Moucari R, Martinot-Peignoux M, Mackiewicz V, et al. Influence of genotype on hepatitis B surface antigen kinetics in hepatitis B e antigen-negative patients treated with pegylated interferon-alpha2a. Antivir Ther 2009; 14: 1183-8.
68. Bréchot C. Pathogenesis of hepatitis B virus-related hepatocellular carcinoma: old and new paradigms. Gastroenterology 2004; 127 (Suppl. 1): S56-61.